scispace - formally typeset
Y

Yuming Cheng

Researcher at Fudan University

Publications -  9
Citations -  357

Yuming Cheng is an academic researcher from Fudan University. The author has contributed to research in topics: Internal medicine & HBsAg. The author has an hindex of 4, co-authored 5 publications receiving 314 citations. Previous affiliations of Yuming Cheng include Fudan University Shanghai Medical College.

Papers
More filters
Journal ArticleDOI

Expression profiles and function of Toll-like receptors 2 and 4 in peripheral blood mononuclear cells of chronic hepatitis B patients

TL;DR: This study reveals a possible interaction between HBsAg, TLR signaling and the innate immune response, which may partially explain the mechanism of HBV infection induced immuno-tolerance.
Journal ArticleDOI

Hepatitis B Virus Surface Antigen Selectively Inhibits TLR2 Ligand–Induced IL-12 Production in Monocytes/Macrophages by Interfering with JNK Activation

TL;DR: It is demonstrated that HBsAg selectively inhibits Pam3csk4- stimulated IL-12 production in M/MΦs by blocking the JNK–MAPK pathway and provide a mechanism by which HBV evades immunity and maintains its persistence.
Journal ArticleDOI

Measles virus infection in adults induces production of IL-10 and is associated with increased CD4+ CD25+ regulatory T cells.

TL;DR: The results show that adult measles patients in the acute phase of the disease have a mixed Th1/Th2 type response, accompanied with severe immunosuppression of both innate and adaptive responses including suppression of type I IFN.
Journal ArticleDOI

Whole recombinant Hansenula polymorpha expressing hepatitis B virus surface antigen (yeast-HBsAg) induces potent HBsAg-specific Th1 and Th2 immune responses

TL;DR: Temperature-killed whole recombinant Hansenula polymorpha yeast expressing hepatitis B surface antigen (yeast-HBsAg) was generated, and the immune responses elicited by yeast- HBsAg were investigated in mice, suggesting that yeast-HBSAg may be an ideal candidate for an effective vaccine for the control of chronic hepatitis B virus (HBV) infection.
Journal ArticleDOI

Metabolic associated fatty liver disease better identifying patients at risk of liver and cardiovascular complications

TL;DR: A nomenclature of metabolic associated fatty liver disease (MAFLD) with a new definition was proposed in 2020 instead of the previous "non-alcoholic fatty liver diseases" (NAFLD), whether it better coheres with the clinical demand remains controversial as mentioned in this paper .